Trenton, NJ (November 29, 2016) – BioNJ’s first-ever Beyond Value Frameworks Workshop is taking place next Thursday, December 8 at Amicus Therapeutics, Cranbury, NJ. Designed for individuals responsible for pricing, policy, market access and reimbursement, attendees will learn how to become engaged and influencial regarding framework decisions, develop partnerships to challenge value assessments, discuss ways to measure Patient-centered value and learn about new analytic computational platforms that can demonstrate and calculate drug value.
Because Patients Can’t WaitSM, BioNJ developed this special workshop, with extensive guidance from industry thought leaders, to provide information, tools and strategies for understanding and dealing with value frameworks. Panelists will also discuss alternative approaches to ensure that Patient-value shapes access.
“Ironically value frameworks pose a real threat to value,” said BioNJ President and CEO Debbie Hart. “Innovative medicines save and extend lives, improve the quality of life and drive value to the healthcare system. Value frameworks threatens Patients’ ability to get what they need. Patient access cannot be blocked.”
The interactive program, featuring hands-on sessions and a networking lunch, is the first step in ensuring that this important dialogue happens. Participants will include Patients, Patient advocacy groups, biopharmaceutical companies, payers and government. Click here for the agenda.
Panelists include: Kathleen Arntsen, President & CEO, Lupus and Allied Diseases Association;Gary Binder, Former Director, U.S. Market Access, Celgene Corporation; Marc Boutin, CEO, National Health Council; John Crowley, Chairman of the Board & CEO, Amicus Therapeutics;Jennifer M. Hinkel, Partner, McGivney Global Advisors; Jayne Gershkowitz, Chief Patient Advocate, Amicus Therapeutics; Robert Goldberg, Ph.D., Vice President & Co-Founder, Center for Medicine in the Public Interest; Iya Khalil, Ph.D., Chief Commercial Officer, Executive Vice President and Co-founder, GNS Healthcare; Dan Leonard, President, National Pharmaceutical Council; Kevin Rigby, General Manager, Rigby Consulting; Assemblyman Adam Taliaferro, Strategic Planning, State and Federal Payment Agencies, Bristol-Myers Squibb; Bob Tufts, Founder, My Life is Worth It; and Tiffany Westrich-Robertson, CEO, International Foundation for Autoimmune Arthritis.
The registration price for BioNJ Members and affiliated organizations is $195 and $295 for Future Members. Click here to register. (This event is closed to media.) For more information, visit www.BioNJ.org or call (609) 890-3185.
BioNJ, The Gateway to Health, is a network of more than 400 Members representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t WaitSM, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
Vice President, Communications and Marketing